OSE Immunotherapeutics SA
F:6OP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
OSE Immunotherapeutics SA
F:6OP
|
FR |
|
G
|
Grenergy Renovables SA
XMUN:5GR
|
ES |
|
D
|
Duluth Holdings Inc
F:6DU
|
US |
|
Schindler Holding AG
SIX:SCHP
|
CH |
Intrinsic Value
Is 6OP undervalued or overvalued?
See the intrinsic value estimate for 
OSE Immunotherapeutics SA and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
6OP looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with 6OP’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What OSE Immunotherapeutics Does
OSE Immunotherapeutics is a French biotechnology company that develops immunotherapies for cancer, autoimmune disease, and inflammation. It does not sell a broad line of finished medicines; instead, it builds drug candidates that are meant to train or redirect the immune system, with a focus on therapies that can be used in areas where existing treatments are limited or not enough.
- Headquarters
- France FR
- Employees
- 64
- IPO date
- Mar 30, 2015
Earnings Waterfall
OSE Immunotherapeutics SA
The intrinsic value for OSE Immunotherapeutics SA (6OP) under the Base Case is hidden EUR.
Compared with the current market price of 1.992 EUR, the stock appears hidden.